Welcome to our dedicated page for Novanta news (Ticker: NOVT), a resource for investors and traders seeking the latest updates and insights on Novanta stock.
Novanta Inc. (Nasdaq: NOVT) is a global supplier of core technology solutions for medical, life science, and advanced industrial original equipment manufacturers. As a trusted technology partner to medical and advanced technology equipment manufacturers, the company frequently features in news related to its financial performance, capital markets activity, and participation in investor and industry conferences.
News about Novanta often includes quarterly earnings releases and related conference call announcements, where the company reports GAAP results alongside non-GAAP metrics such as Adjusted EBITDA, Adjusted Diluted EPS, and Organic Revenue Growth. These updates provide insight into how its precision medicine, precision manufacturing, medical solutions, robotics and automation, and advanced surgery businesses are performing.
Investors can also expect coverage of capital structure developments, such as the offering and pricing of tangible equity units that combine prepaid stock purchase contracts with senior amortizing notes, as well as amendments to credit agreements and details of senior credit facilities. Announcements about share repurchase authorizations by the Board of Directors are another recurring news theme, reflecting decisions on capital allocation.
In addition, Novanta regularly appears in conference and investor event schedules, including healthcare and industrial conferences hosted by firms such as J.P. Morgan, Baird, Jefferies, and CJS Securities. These events highlight management’s engagement with the investment community and provide forums for discussing strategy and market positioning.
This news page aggregates such items in one place, helping readers follow Novanta’s earnings announcements, financing activities, share repurchase plans, and public presentations over time.
Novanta reported Q4 and full year 2020 results, highlighting revenue of $147.5 million, down 7.6% year-over-year. For the full year, revenue declined 5.7% to $590.6 million. Despite a decrease in organic growth of 10.1% for Q4, operating income rose to $17.1 million, and net income reached $12.7 million. Adjusted diluted EPS for Q4 was $0.53, slightly down from $0.55. The company forecasts Q1 2021 revenue of $155 million to $157 million and plans to launch significantly more new products. Operating cash flow remained strong at $46.6 million for Q4.
Novanta Inc. (Nasdaq: NOVT) will announce its fourth quarter and full year 2020 results on March 1, 2021. A conference call is scheduled for the same day at 10:00 a.m. ET, accessible via phone or through a live webcast on the Company's website. A replay of the call will be available approximately three hours after its conclusion, lasting until April 5, 2021. Novanta is a global supplier of advanced technology solutions that provide OEMs in healthcare and industrial sectors with a competitive edge through precision and technical expertise.
Novanta Inc. (Nasdaq:NOVT), a leader in technology solutions for medical and advanced industrial OEMs, announced that CEO Matthijs Glastra will present at the virtual J.P. Morgan Healthcare Conference on January 13, 2021. Novanta specializes in photonics, vision, and precision motion technologies, providing clients with high-performance sub-systems tailored to their requirements. The company's growth is driven by a team committed to innovation and customer success. For more information, visit www.novanta.com.
Novanta Inc. (Nasdaq: NOVT) announced that its CFO, Robert Buckley, will present at the CJS Securities 21st Annual New Ideas for the New Year Conference on January 13, 2021. Novanta specializes in technology solutions for medical and advanced industrial OEMs, leveraging expertise in photonics, vision, and precision motion. The company focuses on engineering high-performance components and subsystems tailored for demanding applications, contributing to its growth through innovation and customer success.
Novanta Inc. (NASDAQ: NOVT) reported third-quarter 2020 financial results, showing GAAP revenue of $142.9 million, down 7.2% from $154.1 million in Q3 2019. Operating income decreased to $11.9 million, and net income was $8.3 million, compared to $12.8 million and $8.9 million, respectively, in the prior year. Adjusted EBITDA was $30.2 million, slightly lower than $31.0 million in Q3 2019. The company generated significant operating cash flow of $42.1 million, up from $7.0 million last year. Novanta anticipates fourth-quarter revenue of $144-$149 million, with continued focus on product innovation.
Novanta Inc. (Nasdaq: NOVT) announces that CEO Matthijs Glastra and CFO Robert Buckley will present at the Baird Global Industrial Conference on November 11, 2020. The company is renowned for providing core technology solutions, enhancing the competitive edge of medical and industrial OEMs through expertise in photonics, vision, and precision motion. Novanta's common shares are listed on Nasdaq under the ticker symbol 'NOVT'. For more details, visit www.novanta.com.
Novanta Inc. (Nasdaq: NOVT) will release its third quarter 2020 results on November 10, 2020. A conference call to discuss these results is scheduled for the same day at 10:00 a.m. ET. Investors can join by dialing (888) 346-3959 or through a live webcast on the company’s Investor Relations page. A replay of the call will be available three hours post-conclusion until January 4, 2020.
Novanta specializes in technology solutions for healthcare and industrial OEMs.